United States News Todas as matérias

Micron Technology (NASDAQ:MU) reported record third quarter fiscal 2026 revenue of $41.46 billion, significantly higher than $23.86 billion in the prior quarter and $9.30 billion a year ago.

Methode Electronics (NYSE:MEI) reported fourth-quarter fiscal 2026 net sales of $298.1 million, representing a 15.9% increase compared with the same period last year.

Worthington Steel (NYSE:WS) said its board of directors has declared a quarterly dividend of $0.16 per common share.

Pfizer (NYSE:PFE) has been dismissed from a large U.S. antitrust lawsuit in which multiple states accused drugmakers of fixing prices for generic medications.

Chemours Company (NYSE:CC) announced a settlement with the U.S. Environmental Protection Agency and West Virginia regulators to resolve claims related to PFAS discharges at three operating sites.

OpenAI has unveiled its first custom-designed AI chip, called Jalapeño, developed in partnership with Broadcom (NASDAQ:AVGO).

Alibaba Group Holding (NYSE:BABA) has filed a federal lawsuit in San Jose, California, against the U.S. Department of Defense, challenging its designation on a list of companies alleged to have ties to China’s military.

CMC (NYSE:CMC) declared a regular quarterly cash dividend of $0.20 per share on its common stock.

This payment represents the company’s 247th consecutive quarterly dividend.

ALZpath has entered a global licensing agreement with Abbott (NYSE:ABT) to support the development of an in vitro diagnostic blood test for Alzheimer’s disease using its proprietary pTau217 antibody.

LENZ Therapeutics (NASDAQ:LENZ) and Arrotex Pharmaceuticals have signed an exclusive license and commercialization agreement for VIZZ in Australia and New Zealand.

Oil prices declined on Wednesday, with Brent crude falling 1% to $76.30 per barrel and West Texas Intermediate dropping 1.1% to $72.43, extending losses to multi-month lows.

Eli Lilly (NYSE:LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders.

Hudbay Minerals (NYSE:HBM) has completed its all-share acquisition of Arizona Sonoran Copper Company, with Arizona Sonoran now operating as a wholly owned subsidiary of Hudbay.

Paychex (NASDAQ:PAYX) reported fourth-quarter fiscal 2026 revenue of $1.61 billion, reflecting a 12% increase compared with the same period last year.

InMode (NASDAQ:INMD) said its board received an unsolicited proposal on June 17, 2026 from M.N. Business Strategy to acquire all outstanding ordinary shares it does not already own for $16.20 per share in cash.

Kaspi.kz (NASDAQ:KSPI) received regulatory approval from Türkiye’s Banking Regulation and Supervision Agency (BDDK) to acquire Rabobank A.Ş., a fully licensed Turkish bank.

EXL Service Holdings (NASDAQ:EXLS) signed a definitive agreement to acquire iMerit, a company specializing in AI model training, evaluation, and reinforcement learning services, in a transaction valued at up to $310 million.

Qualcomm Incorporated (NASDAQ:QCOM) has reached an agreement to acquire Modular, strengthening Qualcomm Technologies’ software foundation for generative and agentic AI across data center and edge environments.

Gaxos (NASDAQ:GXAI) completed the sale of its gaming assets, including mobile games and Gaxos Gaming Labs, to privately held Game Foundry AI in an all-stock transaction valued at approximately $1.76 million.

PodcastOne (NASDAQ:PODC) reported record fiscal 2026 revenue of $61.7 million, an increase of 18% from the prior year.

Viking Therapeutics (NASDAQ:VKTX) has started a Phase 1 single ascending dose study of VK3019 in healthy adults with a body mass index of 30 or higher.

Cognition Therapeutics (NASDAQ:CGTX) reported FDA alignment on key elements of a pivotal Phase 3 trial of zervimesine (CT1812) for the treatment of psychosis in dementia with Lewy bodies (DLB).

ADC Therapeutics (NYSE:ADCT) announced a strategic reorganization aimed at prioritizing its ZYNLONTA franchise and advancing key clinical programs including LOTIS-5 and LOTIS-7.

REGENXBIO (NASDAQ:RGNX) said it has completed dosing in the confirmatory study of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy, marking completion of its registrational development program.